Purpose The purpose of this study was to analyze the association between bleeding events
and coagulation assays including activated partial thromboplastin time (APTT) and …

Background: The distribution of activated partial thromboplastin time (APTT) in nonvalvular
atrial fibrillation (NVAF) patients under dabigatran therapy remains to be clarified. Methods …

Background Dabigatran has demonstrated promising results for the prevention of strokes in
patients with non-valvular atrial fibrillation (NVAF). However, there have been episodes of …

Purpose: To assess the predicted rate and the factors associated with bleeding events
among patients with non-valvular atrial fibrillation (NVAF) receiving dabigatran therapy …

Background: The association between peripheral leukocyte count and bleeding events in
nonvalvular atrial fibrillation (NVAF) patients treated with dabigatran remains unclear. This …

We aimed to develop a pharmacokinetic (PK) and pharmacodynamic (PD) model from
healthy Chinese subjects and real-world non-valvular atrial fibrillation (NVAF) patients. We …

Background: Few data exist regarding frequency and predictors of bleeding complications
associated with anticoagulant therapy using dabigatran in Japanese patients with atrial …

Background Activated partial thromboplastin time (aPTT) is recommended for monitoring
anticoagulant activity in dabigatran-treated patients; however, there are limited data in …

Introduction Prior use of direct oral anticoagulants has been associated with reduced stroke
severity in patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to …

This study aimed to evaluate the variability of dabigatran plasma concentration and the
association with clinical events in Chinese patients treated with dabigatran etexilate (DE) for …